Breast Cancer Research and Treatment

, Volume 93, Issue 1, pp 3–11 | Cite as

Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  • Noël DybdalEmail author
  • Grazyna Leiberman
  • Steven Anderson
  • Bryan McCune
  • Alex Bajamonde
  • Robert L. Cohen
  • Robert D. Mass
  • Corsee Sanders
  • Michael F. Press


Purpose. To evaluate the concordance between HER2 gene amplification, determined by fluorescence in situ hybridization (FISH), and HER2 protein overexpression assessed by an immunohistochemical (IHC) assay. The IHC protocol used was a research assay, known as the Clinical Trial Assay (CTA), developed to select women with metastatic breast cancer (MBC) for three pivotal clinical trials of trastuzumab therapy.

Methods. A direct-labeled, dual-probe FISH assay was used to determine HER2 amplification in 623 fixed breast cancer tissue specimens. These specimens had been stored as paraffin-embedded sections for 2ᾢ5 years. All specimens had been analyzed for HER2 protein expression by the CTA. To assess the reproducibility of FISH results in archived material, we evaluated a separate group of 617 breast cancer tissue specimens at two di erent laboratories.

Results. Informative FISH results were available for 529 (85%) of the 623 specimens. Overall concordance between FISH and IHC results was 82% (95% CI; 78ᾢ85%). Assay agreement between FISH results and specimens with immunostaining scores of 0, 1+, and 3+ were 97, 93 and 89%, respectively. However, only 24% of specimens with 2+ immunostaining scores had HER2 amplification by FISH; there was assay disagreement in 76% of specimens in this IHC subgroup. Interlaboratory FISH concordance was 92% (95% CI; 89ᾢ94%), indicating very good assay reproducibility in these archived specimens.

Conclusion. HER2 status determined by CTA-IHC and FISH are significantly correlated; however, differences between these two assays can a ect patient selection for trastuzumab therapy.


fluorescence in situ hybridization (FISH) HER2 immunohistochemistry (IHC) metastatic breast cancer (MBC) trastuzumab 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akiyama, T, Sudo, C, Ogawara, H, Toyoshima, K, Yamamoto, T 1986The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activityScience23216441646PubMedGoogle Scholar
  2. Coussens, L, Yang-Feng, TL, Liao, YC, Chen, E, Gray, A, McGrath, J, Seeburg, PH, Libermann, TA, Schlessinger, J, Francke, U,  et al. 1985Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogeneScience23011321139Google Scholar
  3. Stern, DF, Heffernan, PA, Weinberg, RA 1986p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activityMol Cell Biol617291740PubMedGoogle Scholar
  4. Slamon, DJ, Clark, GM, Wong, SG, Levin, WJ, Ullrich, A, McGuire, WL 1987Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience235177182Google Scholar
  5. Pauletti, G, Dandekar, S, Rong, H 1998A large-scale FISH study of HER-2/neu gene amplification in breast cancer.Proc Am Assoc Cancer Res 39345(Abstract 2352)Google Scholar
  6. Slamon, DJ, Godolphin, W, Jones, LA, Holt, JA, Wong, SG, Keith, DE, Levin, WJ, Stuart, SG, Udove, J, Ullrich, A,  et al. 1989Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience244707712Google Scholar
  7. Kallioniemi, OP, Kallioniemi, A, Kurisu, W, Thor, A, Chen, LC, Smith, HS, Waldman, FM, Pinkel, D, Gray, JW 1992ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridizationProc Natl Acad Sci USA8953215325PubMedGoogle Scholar
  8. Gusterson, BA, Gelber, RD, Goldhirsch, A, Price, KN, Save-Soderborgh, J, Anbazhagan, R, Styles, J, Rudenstam, CM, Golouh, R, Reed, R,  et al. 1992Prognostic importance of c-erbB-2 expression in breast cancer.International (Ludwig) Breast Cancer Study GroupJ Clin Oncol1010491056Google Scholar
  9. Andrulis, IL, Bull, SB, Blackstein, ME, Sutherland, D, Mak, C, Sidlofsky, S, Pritzker, KP, Hartwick, RW, Hanna, W, Lickley, L, Wilkinson, R, Qizilbash, A, Ambus, U, Lipa, M, Weizel, H, Katz, A, Baida, M, Mariz, S, Stoik, G, Dacamara, P, Strongitharm, D, Geddie, W, McCready, D 1998neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.Toronto Breast Cancer Study GroupJ Clin Oncol1613401349PubMedGoogle Scholar
  10. Press, MF, Pike, MC, Chazin, VR, Hung, G, Udove, JA, Markowicz, M, Danyluk, J, Godolphin, W, Sliwkowski, M, Akita, R,  et al. 1993Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent diseaseCancer Res5349604970PubMedGoogle Scholar
  11. Press, MF, Bernstein, L, Thomas, PA, Meisner, LF, Zhou, JY, Ma, Y, Hung, G, Robinson, RA, Harris, C, El-Naggar, A, Slamon, DJ, Phillips, RN, Ross, JS, Wolman, SR, Flom, KJ 1997HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomasJ Clin Oncol1528942904PubMedGoogle Scholar
  12. Chazin, VR, Kaleko, M, Miller, AD, Slamon, DJ 1992Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptorOncogene718591866PubMedGoogle Scholar
  13. Carter, P, Presta, L, Gorman, CM, Ridgway, JB, Henner, D, Wong, WL, Rowland, AM, Kotts, C, Carver, ME, Shepard, HM 1992Humanization of an anti-p185HER2 antibody for human cancer therapyProc Natl Acad Sci USA8942854289PubMedGoogle Scholar
  14. Cobleigh, MA, Vogel, CL, Tripathy, D, Robert, NJ, Scholl, S, Fehrenbacher, L, Wolter, JM, Paton, V, Shak, S, Lieberman, G, Slamon, DJ 1999Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol1726392648PubMedGoogle Scholar
  15. Slamon, DJ, Leyland-Jones, B, Shak, S, Fuchs, H, Paton, V, Bajamonde, A, Fleming, T, Eiermann, W, Wolter, J, Pegram, M, Baselga, J, Norton, L 2001Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med344783792CrossRefPubMedGoogle Scholar
  16. Vogel, CL, Cobleigh, MA, Tripathy, D, Gutheil, JC, Harris, LN, Fehrenbacher, L, Slamon, DJ, Murphy, M, Novotny, WF, Burchmore, M, Shak, S, Stewart, SJ, Press, M 2002Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol20719726CrossRefPubMedGoogle Scholar
  17. Pauletti, G, Godolphin, W, Press, MF, Slamon, DJ 1996Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridizationOncogene136372PubMedGoogle Scholar
  18. Pauletti, G, Dandekar, S, Rong, H, Ramos, L, Peng, H, Seshadri, R, Slamon, DJ 2000Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistryJ Clin Oncol1836513664PubMedGoogle Scholar
  19. Press, MF, Hung, G, Godolphin, W, Slamon, DJ 1994Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expressionCancer Res5427712777PubMedGoogle Scholar
  20. Tubbs, RR, Pettay, JD, Roche, PC, Stoler, MH, Jenkins, RB, Grogan, TM 2001Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the messageJ Clin Oncol1927142721PubMedGoogle Scholar
  21. Lebeau, A, Deimling, D, Kaltz, C, Sendelhofert, A, Iff, A, Luthardt, B, Untch, M, Lohrs, U 2001Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridizationJ Clin Oncol19354363PubMedGoogle Scholar
  22. Jimenez, RE, Wallis, T, Tabasczka, P, Visscher, DW 2000Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridizationMod Pathol133745CrossRefPubMedGoogle Scholar
  23. Bartlett, JM, Going, JJ, Mallon, EA, Watters, AD, Reeves, JR, Stanton, P, Richmond, J, Donald, B, Ferrier, R, Cooke, TG 2001Evaluating HER2 amplification and overexpression in breast cancerJ Pathol195422428CrossRefPubMedGoogle Scholar
  24. Diaz, NM 2001Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapyCancer Control8415418PubMedGoogle Scholar
  25. Jacobs, TW, Gown, AM, Yaziji, H, Barnes, MJ, Schnitt, SJ 1999Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancerJ Clin Oncol1719741982PubMedGoogle Scholar
  26. Kakar, S, Puangsuvan, N, Stevens, JM, Serenas, R, Mangan, G, Sahai, S, Mihalov, ML 2000HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survivalMol Diagn5199207CrossRefPubMedGoogle Scholar
  27. Ridolfi, RL, Jamehdor, MR, Arber, JM 2000HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approachMod Pathol13866873CrossRefPubMedGoogle Scholar
  28. Perez, EA, Roche, PC, Jenkins, RB, Reynolds, CA, Halling, KC, Ingle, JN, Wold, LE 2002HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridizationMayo Clin Proc77148154PubMedGoogle Scholar
  29. Thomson, TA, Hayes, MM, Spinelli, JJ, Hilland, E, Sawrenko, C, Phillips, D, Dupuis, B, Parker, RL 2001HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridizationMod Pathol1410791086CrossRefPubMedGoogle Scholar
  30. Hoang, MP, Sahin, AA, Ordonez, NG, Sneige, N 2000HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinomaAm J Clin Pathol113852859CrossRefPubMedGoogle Scholar
  31. Seidman , AD, Fornier, MN, Esteva, FJ, Tan, L, Kaptain, S, Bach, A, Panageas, KS, Arroyo, C, Valero, V, Currie, V, Gilewski, T, Theodoulou, M, Moynahan, ME, Moasser, M, Sklarin, N, Dickler, M, D‘Andrea, G, Cristofanilli, M, Rivera, E, Hortobagyi, GN, Norton, L, Hudis, CA 2001Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplificationJ Clin Oncol1925872595PubMedGoogle Scholar
  32. Persons, DL, Borelli, KA, Hsu, PH 1997Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridizationMod Pathol10720727PubMedGoogle Scholar
  33. Tsuda, H, Akiyama, F, Terasaki, H, Hasegawa, T, Kurosumi, M, Shimadzu, M, Yamamori, S, Sakamoto, G 2001Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaInterobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer9229652974Google Scholar
  34. Birner, P, Oberhuber, G, Stani, J, Reithofer, C, Samonigg, H, Hausmaninger, H, Kubista, E, Kwasny, W, Kandioler-Eckersberger, D, Gnant, M, Jakesz, R 2001Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancerClin Cancer Res716691675PubMedGoogle Scholar
  35. Press, MF, Slamon, DJ, Flom, KJ, Park, J, Zhou, JY, Bernstein, L 2002Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimensJ Clin Oncol2030953105PubMedGoogle Scholar
  36. Paik, S, Bryant, J, Tan-Chiu, E, Romond, E, Hiller, W, Park, K, Brown, A, Yothers, G, Anderson, S, Smith, R, Wickerham, DL, Wolmark, N 2002Real-world performance of HER2 testingᾢNational Surgical Adjuvant Breast and Bowel Project experienceJ Natl Cancer Inst94852854PubMedGoogle Scholar
  37. Fleiss, J 1981Statistical Methods of Rates and Proportions2John Wiley & Sons, IncNew York217Google Scholar
  38. Mass RD, Press MF, Anderson S: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 2005 (in press).Google Scholar
  39. Ross, JS, Fletcher, JA 1998The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapyStem Cells16413428PubMedGoogle Scholar
  40. Battifora, H, Kopinski, M 1986The influence of protease digestion and duration of fixation on the immunostaining of keratinsA comparison of formalin and ethanol fixation. J Histochem Cytochem3410951100Google Scholar
  41. Penault-Llorca, F, Adelaide, J, Houvenaeghel, G, Hassoun, J, Birnbaum, D, Jacquemier, J 1994Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixationJ Pathol1736575CrossRefPubMedGoogle Scholar
  42. Jacobs, TW, Gown, AM, Yaziji, H, Barnes, MJ, Schnitt, SJ 1999Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring systemJ Clin Oncol1719831987PubMedGoogle Scholar
  43. MA, Owens, BC, Horten, MM, Da Silva 2004HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissuesClin Breast Cancer56369PubMedGoogle Scholar
  44. Press MF SG, Bernstein L, Mirlacher M, Villalobos I, Zhou J, Riva A, Nabholtz JM, Slamon DJ: Diagnostic evaluation of HER-2/neu as a molecular therapeutic target: local testing versus centralized FISH testing. Lab Invest 83: 43a, 2003Google Scholar
  45. Niehans, GA, Singleton, TP, Dykoski, D, Kiang, DT 1993Stability of HER-2/neu expression over time and at multiple metastatic sitesJ Natl Cancer Inst8512301235PubMedGoogle Scholar
  46. Vincent-Salomon, A, Jouve, M, Genin, P, Freneaux, P, Sigal-Zafrani, B, Caly, M, Beuzeboc, P, Pouillart, P, Sastre-Garau, X 2002HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer9421692173CrossRefPubMedGoogle Scholar
  47. Simon, R, Nocito, A, Hubscher, T, Bucher, C, Torhorst, J, Schraml, P, Bubendorf, L, Mihatsch, MM, Moch, H, Wilber, K, Schotzau, A, Kononen, J, Sauter, G 2001Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancerJ Natl Cancer Inst9311411146Google Scholar
  48. Masood, S, Bui, MM 2000Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical studyAnn Clin Lab Sci30259265PubMedGoogle Scholar
  49. Paik, S, Tan-Chiu, E, Bryant, J, Romond, E, Brown, A, Mull, J, Hiller, W, Finnigan, M, Wolmark, N 2002Successful quality assurance program for HER2 testing in the NSABP trial for HerceptinBreast Cancer Res Treat 76S31Google Scholar
  50. Bartlett, J, Mallon, E, Cooke, T 2003The clinical evaluation of HER-2 status: which test to useJ Pathol199411417CrossRefPubMedGoogle Scholar
  51. CAP,  2002Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testingArch Pathology Lab Med126803808Google Scholar
  52. Diest , PJ vDP, Henzen-Logmans, SC, Berns, E, Burg, ME, Green, J, Vergote, I 1997A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative GroupJ Clin Pathol50801804PubMedGoogle Scholar
  53. Going, JJ, Mallon, L, Reeves, JR, Watters, AD, Richmond, J, Donald, B, Ferrier, R, Cooke, T, Bartlett, J 2000Inter-observer agreement in assessing C-ERBB-2 status in breast cancer: immunhistochemistry and FISH.J Pathol 19019AGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Noël Dybdal
    • 1
    • 4
    Email author
  • Grazyna Leiberman
    • 1
  • Steven Anderson
    • 2
  • Bryan McCune
    • 2
  • Alex Bajamonde
    • 1
  • Robert L. Cohen
    • 1
  • Robert D. Mass
    • 1
  • Corsee Sanders
    • 1
  • Michael F. Press
    • 3
  1. 1.Genentech Inc.South San Francisco
  2. 2.Laboratory Corporation of America
  3. 3.Norris Comprehensive Cancer CenterUniversity of Southern CaliforniaLos AngelesUSA
  4. 4.Genentech Inc.South San FranciscoUSA

Personalised recommendations